How do I start and titrate tirzepatide (Mounjaro) in an adult with type 2 diabetes or obesity who has no personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2?

How to Use Mounjaro (Tirzepatide)

Start tirzepatide at 2.5 mg subcutaneously once weekly, then increase to 5 mg after 4 weeks, with further dose escalations in 2.5 mg increments every 4 weeks as needed for glycemic control, up to a maximum of 15 mg weekly in adults or 10 mg weekly in pediatric patients aged 10 years and older. 1

Starting Dose and Titration Schedule

• Initial dose: 2.5 mg subcutaneously once weekly 1
• After 4 weeks: Increase to 5 mg once weekly 1
• Subsequent escalations: Increase by 2.5 mg increments after at least 4 weeks on current dose if additional glycemic control is needed 1
• Maximum dose: 15 mg weekly for adults; 10 mg weekly for pediatric patients ≥10 years 1

The 2.5 mg starting dose is not a therapeutic dose—it serves solely to minimize gastrointestinal side effects during initiation 2. Real-world data shows 84.1% of patients appropriately initiate at ≤5 mg, with the mean time to first dose escalation being 59 days 3. The slow monthly titration is essential because gastrointestinal adverse events occur most commonly during dose escalation 2.

Administration Instructions

• Frequency: Once weekly, on the same day each week 1
• Timing: Any time of day, with or without meals 1
• Route: Subcutaneous injection in abdomen, thigh, or back of upper arm (if administered by another person) 1
• Rotation: Change injection sites with each dose 1
• Appearance: Solution should be clear and colorless to slightly yellow; do not use if particulate matter or discoloration present 1

Missed Dose Management

If a dose is missed:

• ≤4 days late: Administer as soon as possible, then resume regular weekly schedule 1
• >4 days late: Skip the missed dose and give next dose on regularly scheduled day 1
• The day of weekly administration can be changed if needed, provided at least 72 hours (3 days) pass between doses 1

Key Clinical Considerations

Combination Therapy Rules

Tirzepatide should NOT be combined with GLP-1 receptor agonists but can be used with SGLT-2 inhibitors and finerenone 4. When switching from a GLP-1 receptor agonist to tirzepatide in patients at higher cardiovascular or kidney risk, initiate or continue an SGLT-2 inhibitor to maintain cardiovascular and renal protection 4.

Concomitant Medications Requiring Dose Adjustment

When using tirzepatide with insulin or insulin secretagogues (e.g., sulfonylureas), reduce the dose of these medications to lower hypoglycemia risk 1. Tirzepatide delays gastric emptying and may impact absorption of oral medications 1.

Oral Contraceptive Consideration

For females using oral contraceptives, switch to a non-oral method or add barrier contraception for 4 weeks after initiation and for 4 weeks after each dose escalation due to potential reduced absorption 1.

Managing Gastrointestinal Side Effects

The most common adverse reactions (occurring in ≥5% of patients) are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain 1. To mitigate these:

• Always start at the lowest dose (2.5 mg) 2
• Titrate slowly (monthly intervals minimum) 2
• Counsel patients to avoid fatty foods, not eat past fullness, and eat smaller amounts more frequently 2
• Monitor for dehydration and renal impairment in patients with vomiting or diarrhea 2
• If treatment is paused or discontinued, restart at low dose and re-titrate to allow body re-acclimation 2

Real-world data shows 17.2% of patients experience dose de-escalation (mean time 104.8 days), indicating tolerance issues can be managed by stepping back 3.

Absolute Contraindications

Do not use tirzepatide in patients with:

• Personal or family history of medullary thyroid carcinoma (MTC) 1
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1
• Known serious hypersensitivity to tirzepatide or excipients 1

Tirzepatide causes thyroid C-cell tumors in rats; while human relevance is unknown, counsel patients about potential MTC risk and symptoms (neck mass, dysphagia, dyspnea, persistent hoarseness) 1.

Important Safety Monitoring

• Acute pancreatitis: Discontinue if suspected (persistent severe abdominal pain) 1
• Acute kidney injury: Monitor renal function in patients with volume depletion from gastrointestinal adverse reactions 1
• Gallbladder disease: Consider if cholelithiasis suspected 1
• Diabetic retinopathy: Monitor patients with history of diabetic retinopathy for progression 1
• Pulmonary aspiration risk: Instruct patients to inform providers of planned surgeries or procedures requiring anesthesia 1

Expected Outcomes

Based on the SURPASS and SURMOUNT trials 2:

• HbA1c reduction: 1.9-2.2% in type 2 diabetes 2
• Weight loss: 12.8-14.7% in patients with diabetes and obesity; 22.5% at 15 mg dose in obesity alone 2
• Adherence: Real-world 6-month adherence (PDC ≥80%) is 57.5% with 73.3% persistence 3

The 2025 AACE guidelines position tirzepatide as a second-generation obesity medication with superior weight loss compared to GLP-1 receptor agonists, though GLP-1 receptor agonists have higher certainty evidence for cardiovascular and kidney benefits 2. The 2025 BMJ guideline suggests tirzepatide for adults with obesity (weak recommendation), noting that decision-makers should weigh larger weight loss benefits against higher certainty cardiovascular/kidney benefits offered by GLP-1 receptor agonists 4.